Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 13/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14666734 | 0.82 | MAOB (0.41) | MAOBCYP2D6LMNAPOLBNPSR1 | |
| SCHEMBL14666701 | 0.80 | OPRD1 (0.40) | OPRD1KCNH2CYP2D6OPRK1 | |
| SCHEMBL12082058 | 0.79 | OPRD1 (0.38) | OPRD1KCNH2MAOBCYP2D6OPRK1 | |
| SCHEMBL9577755 | 0.75 | OPRD1 (0.59) | OPRD1KCNH2CYP2D6OPRK1 | |
| SCHEMBL12081862 | 0.73 | NR3C2 (0.48) | OPRD1KCNH2OPRK1 | |
| SCHEMBL13566251 | 0.73 | OPRD1 (0.56) | OPRD1KCNH2MAOBCYP2D6ALDH1A1 | |
| SCHEMBL14666747 | 0.71 | MAOB (0.44) | MAOBCYP2D6LMNAPOLBNPSR1 | |
| SCHEMBL14666753 | 0.71 | PPARG (0.51) | OPRD1KCNH2MAOBLMNAPOLB | |
| SCHEMBL14822727 | 0.71 | PPARA (0.48) | MAOBLMNAPOLBNPSR1ALDH1A1 | |
| SCHEMBL14666743 | 0.68 | MAOB (0.39) | MAOBCYP2D6LMNAPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | OPRD1 268/4885KCNH2 302/4885MAOB 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.